Martinsried / Munich, Germany, May 8, 2015 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its shareholders elected Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich as new members of the Supervisory Board. Dr. Gerald Möller, Dr. Marc Cluzel and Ms. Karin Eastham were re-elected as Supervisory Board Members. In addition, the Company's Annual General Meeting, which took place on Friday, 8 May 2015, approved all resolutions proposed by the Company's Management put to vote at the meeting including:
- The appropriation of the accumulated income for the 2014 financial year.
- The discharge of the members of the Management and Supervisory Boards with respect to the 2014 financial year.
- The appointment of PricewaterhouseCoopers AG as auditor for the 2015 financial year.
- The creation of a new Authorized Capital 2015-I with the option to exclude pre-emptive rights of the shareholders.
- The adjustment in remuneration of the Supervisory Board.
- Amendments to the Articles of Association to reflect Company's current and future strategy.
"We are pleased to announce the new election of Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich, three highly qualified industry experts, and look forward to working with them," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "On behalf of the Management Board and the Company, I would like to thank the resigning Supervisory Board Members Dr. Walter Blättler, Dr. Daniel Camus and Dr. Geoffrey Vernon for their invaluable support over many years in establishing MorphoSys as a leading biopharmaceutical company."
At the Annual General Meeting 2015 of MorphoSys AG, 50.83 % of the voting shares were represented.
More information on the Company's Annual General Meeting including the voting results on all agenda items can be found on http://www.morphosys.com/agm.
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Associate Director Corporate Communications & IR
Manager Corporate Communications & IR
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
Media release http://hugin.info/130295/R/1920171/687853.pdf